- Home
- PRLB vs GYRE Comparison
PRLB vs GYRE Comparison
Compare PRLB & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLB
- GYRE
- Stock Information
- Founded
- PRLB 1999
- GYRE 2002
- Country
- PRLB United States
- GYRE United States
- Employees
- PRLB N/A
- GYRE N/A
- Industry
- PRLB Metal Fabrications
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PRLB Industrials
- GYRE Health Care
- Exchange
- PRLB Nasdaq
- GYRE Nasdaq
- Market Cap
- PRLB 928.0M
- GYRE 755.7M
- IPO Year
- PRLB 2012
- GYRE N/A
- Fundamental
- Price
- PRLB $55.13
- GYRE $8.34
- Analyst Decision
- PRLB Hold
- GYRE Strong Buy
- Analyst Count
- PRLB 3
- GYRE 2
- Target Price
- PRLB $43.50
- GYRE $17.00
- AVG Volume (30 Days)
- PRLB 184.9K
- GYRE 90.0K
- Earning Date
- PRLB 10-31-2025
- GYRE 11-12-2025
- Dividend Yield
- PRLB N/A
- GYRE N/A
- EPS Growth
- PRLB N/A
- GYRE N/A
- EPS
- PRLB 0.61
- GYRE 0.02
- Revenue
- PRLB $508,637,000.00
- GYRE $102,189,000.00
- Revenue This Year
- PRLB $6.76
- GYRE $15.25
- Revenue Next Year
- PRLB $4.74
- GYRE $33.14
- P/E Ratio
- PRLB $89.90
- GYRE $178.16
- Revenue Growth
- PRLB N/A
- GYRE N/A
- 52 Week Low
- PRLB $26.45
- GYRE $6.11
- 52 Week High
- PRLB $55.90
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- PRLB 60.68
- GYRE 56.37
- Support Level
- PRLB $52.47
- GYRE $7.75
- Resistance Level
- PRLB $55.90
- GYRE $8.35
- Average True Range (ATR)
- PRLB 1.84
- GYRE 0.41
- MACD
- PRLB 0.26
- GYRE 0.02
- Stochastic Oscillator
- PRLB 89.95
- GYRE 51.57
About PRLB Proto Labs Inc. Common stock
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.